HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date (Descending) | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Rucaparib | Rubraca | 250 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
NA | Rucaparib | Rubraca | 300 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
NA | Ruxolitinib | Jakafi | 5 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 10 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 15 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 20 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | sonidegib | odozmo | 200 mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2015 | In Use | |||
NA | Sorafenib | Nexavar | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET, CRAF, BRAF | Yes | 2005 | In Use | |||
NA | Sunitinib malate | Sutent | 12.5 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
NA | Sunitinib malate | Sutent | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
NA | Sunitinib malate | Sutent | 37.5 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
NA | Sunitinib malate | Sutent | 50 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
NA | Thioguanine | Tabloid | 40 mg | Chemotherapy | Antimetabolite | Purine Analog | Yes | 1966 | In Use | |||
NA | Trametinib | Mekinist | 0.5 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
NA | Trametinib | Mekinist | 2 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
NA | Trifluridine and Tipiracil | Lonsurf | 15/6.14 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
NA | Trifluridine and Tipiracil | Lonsurf | 20/ 8.19 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
NA | Vandetanib | Caprelsa | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Yes | 2011 | In Use | |||
NA | Vandetanib | Caprelsa | 300 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Yes | 2011 | In Use | |||
NA | Vemurafenib | Zelboraf | 240 mg | Chemotherapy | Enzyme Inhibitor | BRAF | Yes | 2011 | In Use | |||
NA | venetoclax | Venclexta | 10 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
NA | venetoclax | Venclexta | 50 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
NA | venetoclax | Venclexta | 100 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
NA | Vismodegib | Vismodegib | 150 mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2012 | In Use |
Found 716 results in 1 millisecond — Export these results
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.